Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | President and COO | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,088 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,714 · Balance 185,088 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 283 | $23.81 | $6,738.23 |
DisclosureSEC source: 0001214659-23-000270 · marketforms-57984.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,490 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:59 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 35,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-015187 · marketforms-57913.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,773 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of December 19, 2022 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $24.81 | $25,479.87 |
DisclosureSEC source: 0001214659-22-014116 · marketforms-57526.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,289 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 306 | $29.08 | $8,898.48 |
DisclosureSEC source: 0001214659-22-012657 · marketforms-57357.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,316 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 200 | $35.24 | $7,048.00 |
DisclosureSEC source: 0001214659-22-011988 · marketforms-57254.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,622 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 257 | $35.24 | $9,056.68 |
DisclosureSEC source: 0001214659-22-011988 · marketforms-57254.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,822 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $42.81 | $43,965.87 |
DisclosureSEC source: 0001214659-22-010497 · marketforms-56966.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,079 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 305 | $43.52 | $13,273.60 |
DisclosureSEC source: 0001214659-22-009198 · marketforms-56705.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,106 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 457 | $37.08 | $16,945.56 |
DisclosureSEC source: 0001214659-22-008658 · marketforms-56623.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,411 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $36.99 | $37,988.73 |
DisclosureSEC source: 0001214659-22-007385 · marketforms-56318.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,868 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 22, 2022 Filed Apr 26, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 305 | $34.21 | $10,434.05 |
DisclosureSEC source: 0001214659-22-005842 · marketforms-56024.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,895 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 457 | $52.91 | $24,179.87 |
DisclosureSEC source: 0001214659-22-004868 · marketforms-55951.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,200 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c) Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $53.21 | $54,646.67 |
DisclosureSEC source: 0001214659-22-003088 · marketforms-55521.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,425 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 280 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-22-001811 · marketforms-55241.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,705 Underlying: Common Stock · 280 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 379 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-22-001811 · marketforms-55241.xml · derivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,512 Underlying: Common Stock · 379 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 659 | $60.52 | $39,882.68 |
DisclosureSEC source: 0001214659-22-001811 · marketforms-55241.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,452 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 16, 2021. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 379 | $26.66 | $10,104.14 |
DisclosureSEC source: 0001214659-22-001811 · marketforms-55241.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 280 | $23.33 | $6,532.40 |
DisclosureSEC source: 0001214659-22-001811 · marketforms-55241.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 336 | $55.87 | $18,772.32 |
DisclosureSEC source: 0001214659-22-001140 · marketforms-55139.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,452 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 220 | $77.39 | $17,025.80 |
DisclosureSEC source: 0001214659-22-000945 · marketforms-55097.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,788 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 283 | $77.39 | $21,901.37 |
DisclosureSEC source: 0001214659-22-000332 · marketforms-54930.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,008 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,994 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-013796 · marketforms-54838.xml · derivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Underlying: Common Stock · 5,994 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,994 | $75.62 | $453,266.28 |
DisclosureSEC source: 0001214659-21-013796 · marketforms-54838.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,291 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 16, 2021. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,994 | $8.82 | $52,867.08 |
DisclosureSEC source: 0001214659-21-013796 · marketforms-54838.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 6,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-013759 · marketforms-54805.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,291 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of October 1, 2021, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,994 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-013645 · marketforms-54788.xml · derivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,273 Underlying: Common Stock · 5,994 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,994 | $85.09 | $510,029.46 |
DisclosureSEC source: 0001214659-21-013645 · marketforms-54788.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 16, 2021. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,994 | $8.82 | $52,867.08 |
DisclosureSEC source: 0001214659-21-013645 · marketforms-54788.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 219 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-013608 · marketforms-54780.xml · derivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,985 Underlying: Common Stock · 219 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 219 | $82.85 | $18,144.15 |
DisclosureSEC source: 0001214659-21-013608 · marketforms-54780.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 219 | $23.33 | $5,109.27 |
DisclosureSEC source: 0001214659-21-013608 · marketforms-54780.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 241 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-012739 · marketforms-54496.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,204 Underlying: Common Stock · 241 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-012739 · marketforms-54496.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,891 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 586 | $90.00 | $52,740.00 |
DisclosureSEC source: 0001214659-21-012739 · marketforms-54496.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,172 | $87.06 | $102,034.32 |
DisclosureSEC source: 0001214659-21-012739 · marketforms-54496.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,820 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 241 | $23.33 | $5,622.53 |
DisclosureSEC source: 0001214659-21-012739 · marketforms-54496.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-012739 · marketforms-54496.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $110.62 | $113,606.74 |
DisclosureSEC source: 0001214659-21-012187 · marketforms-54356.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 241 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-011156 · marketforms-54141.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,445 Underlying: Common Stock · 241 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-011156 · marketforms-54141.xml · derivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,408 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,758 | $127.23 | $223,670.34 |
DisclosureSEC source: 0001214659-21-011156 · marketforms-54141.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,261 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 241 | $23.33 | $5,622.53 |
DisclosureSEC source: 0001214659-21-011156 · marketforms-54141.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-011156 · marketforms-54141.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2021 Filed Oct 26, 2021 23:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 305 | $117.41 | $35,810.05 |
DisclosureSEC source: 0001214659-21-010775 · ownership.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,261 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · derivative · entry 8 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,686 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,925 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,267 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $104.27 | $281,737.54 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · nonDerivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,566 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.